Pharmacy Books

Bought this for my wife (a dermatologist) and she loves it. Asked me to buy more from the series.

Zoe Draelos is the expert on this topic. This book will teach you a lot

What makes this book stand out from the many hundred others out on the market is that it approaches the effects of herbs on the nervous system from a scientific, rather than pseudo- or anti-scientific, perspective. Rather than viewing herbs as being "alternative" and separate from science, Spinella scrutinizes the empirical evidence for and against the claimed effects of herbs on the brain. This book should be in every psychologist's, psychiatrist's, and physician's book shelf.

This book is a technical, complete and academic discussion of herbs that affect the brain, including therapeutic herbs, sedatives, as well as illicit herbs (herbs used to get a "high"). The author, Marcello Spinella, emphasis the importance of weighing all the risks and benefits of herbal medicine and discusses the latest research from scientific journals. Among the herbs reviewed here are valerian, chamomile, kava, passionflower and ginkgo. Also included is an overview of neuroscience and pharmacology. This is a very good reference book for someone serious about understanding how herbs affect the brain.

As a Medical Transcriptionist I find this book to be an invaluable tool. I use this book not only to find the correct spelling of the drugs but also to find drug usages, doseages, generics, and brand names. I especially like the indication/therapeutic category index. Many times it is difficult to determine exactly what a physician is dictating. I can go to the back, find the illness being treated, and most of the time locate the drug that the doctor has dictated. This book is very comprehensive, up-to-date, and very easy to use. It is the book that I refer to most.

As a Medical Transcriptionist this book is an invaluable resource. I have used it not only to look up the correct spelling of drugs but also to cross reference doseages, generics, and usages. I especially like the indication/therapeutic category index. Many times it is difficult to understand what the physicians dictate, it is helpful to be able to go to the back to see if the drug I think that they have said matches the diagnosis. I highly recommend this book.

Good to read cover to cover and great as a reference for the nuclear pharmacy. I would buy this again at twice the price.

This is the gold standard reference text for Nuclear Pharmacy.
A must have for every Nuclear Medicine Specialist.

The Saunders Pharmaceutical Word Book, 2002 is a must have for every medical transcriptionist. Its the only pharmaceutical book I trust. It has the most up-to-date drug information available. Tired of searching the internet for those newer drug names you just cannot find? Well with this drug book you can end those days. This book is one of very few that really is updated yearly with the new drug names and information. ...Its comprehensive and very easy to use. Its the one reference book I make sure to get yearly.

If you work in the healthcare profession, you should immediately buy this book - unless you're holding out for the new book (2003). I use this book at least once a week at work (I work in a long term care pharmacy) and it never disappoints. The old drugs as well as the new drugs are in there, when the drug has been discontinued as well as the therapeutic classes. And if you're trying to figure out what Paxipam is or whether there's a new formulation for Dimetapp, this book can help you out.
If you're involved in any way with drugs (pharmacy, nursing, medical records/transcriptionist, etc) you'll find this book to be a goldmine of information.
Buy it, it will save you so much time, for example, when you're wondering if Percodan or Percocet has Tylenol in it and is Robitussin really guafensin.

Senn is a great writer. He has written an excellent text on cross-over trials that raises many issues about when such design can be used and what their limitations are. This book covers the gamut of issues in drug development concentrating on important and sometimes subtle issues in clinical trials including design and analysis, intention to treat principle, multiple testing, Bayesian and frequentist approaches and interpretations, meta analysis, regulatory issues and ethics. It also covers cross-over designs, pharmacokinetics, pharmacodynamics and pharmacoeconomics.

The introduction gives you a feeling for the approach in the book and how it splits into two parts. Part I, consisting of chapters 2-5, provides some history of the development of statistical methods and some introductory topics that are fundamental to the discussion in Part II.

Part II is the heart of the book where the practical statistical issues in clinical trials are raised. The text is intended for non-statisticians who work in the pharmaceutical industry but to quote part of Senn's preface he states "Although addressed to the life-scientist it is my hope that many statisticians, in particular those studying medical statistics or embarking on a career in drug development, will also find it useful. Above all I hope that it will help communication between the disciplines: a process by which the statistician stands to benefit as much as any other professional in drug development."

I can really appreciate what Senn has done. He explains the issues of intention-to-treat, washout, multiplicity and other problems that I have had to wrestle with and try to explain to MDs and clinical managers. But even more importantly to me than helping me communicate the many issues that I was aware of, he also raises many subtle issues that I was not aware of. This includes questions of bioequivalence, the use of baseline information and particularly percentage change from baseline versus covariate adjustment, problems of inference regarding measurements taken after titration and issuesw in N of 1 trials. I even learned a few new techniques (e.g. Taves minimiization and Atkinson's generalization of it for allocating patients to treatment groups).

The only complaint I can see is that there is not enough detail. However, remember the text was not designed for statisticians and so much of the mathematics and technicalities are deliberately left out.

But Senn does provides a detailed list of relevant references at the end of each chapter that allows the reader to find in texts and journal articles all the detail one might need. Also to aid with communication there is a large glossary of terms at teh back of the book.

This is a great reference for scientists and statisticians as well!

Senn is a great writer. He has written an excellent text on cross-over trials that raises many issues about when such design can be used and what their limitations are. This book covers the gamut of issues in drug development concentrating on important and sometimes subtle issues in clinical trials including design and analysis, intention to treat principle, multiple testing, Bayesian and frequentist approaches and interpretations, meta analysis, regulatory issues and ethics. It also covers cross-over designs, pharmacokinetics, pharmacodynamics and pharmacoeconomics.
The introduction gives you a feeling for the approach in the book and how it splits into two parts. Part I, consisting of chapters 2-5, provides some history of the development of statistical methods and some introductory topics that are fundamental to the discussion in Part II.

Part II is the heart of the book where the practical statistical issues in clinical trials are raised. The text is intended for non-statisticians who work in the pharmaceutical industry but to quote part of Senn's preface he states "Although addressed to the life-scientist it is my hope that many statisticians, in particular those studying medical statistics or embarking on a career in drug development, will also find it useful. Above all I hope that it will help communication between the disciplines: a process by which the statistician stands to benefit as much as any other professional in drug development."

I can really appreciate what Senn has done. He explains the issues of intention-to-treat, washout, multiplicity and other problems that I have had to wrestle with and try to explain to MDs and clinical managers. But even more importantly to me than helping me communicate the many issues that I was aware of, he also raises many subtle issues that I was not aware of. This includes questions of bioequivalence, the use of baseline information and particularly percentage change from baseline versus covariate adjustment, problems of inference regarding measurements taken after titration and issuesw in N of 1 trials. I even learned a few new techniques (e.g. Taves minimiization and Atkinson's generalization of it for allocating patients to treatment groups).

The only complaint I can see is that there is not enough detail. However, remember the text was not designed for statisticians and so much of the mathematics and technicalities are deliberately left out.

But Senn does provides a detailed list of relevant references at the end of each chapter that allows the reader to find in texts and journal articles all the detail one might need. Also to aid with communication there is a large glossary of terms at teh back of the book.

This is a great reference for scientists and statisticians as well!

This is a very new and unique book that covers the gamut of statistical issues through all phases of drug development. Shao is a distinguished professor from Wisconsin and Chow teaches at Temple but is known for his long career in the pharmaceutical industry.

The book is good for biostatisticians and regulatory affairs specialists as a reference source. All the key statistical issues are addressed and the reader is given the perspective of the ICH and FDA guidance documents. The underlying statistical methodology that justifies the recommendations in the guidances is presented. This is a state-of-the-art book. Shao and Pigeot produced some of the recent research in individual bioequivalence that established a bootstrap procedure as an appropriate way to construct confidence intervals for the problem. Their method is recommended in an FDA guidance document.

But more than just this one example, all the key issues that have been the subject of FDA workshops over the past several years are addressed in this book. These topics include calibration, assay and assay validation, dissolution testing, stability analysis, shelf life estimation, bioequivalence, randomization and blinding, what constitutes substantive evidence in clinical development, therapeutic equivalence and noninferiority, Bayesian approaches in clinical trials, problems involving missing and incomplete data, longitudinal methods, meta-analysis, quality of life studies and instrument validation, and medical imaging.

Other prevalent issues in clinical trials include group sequential methods, hierarchical Bayesian models and multiple testing. These issues are not covered as much in this text as the others we have mentioned. But there is some discussion of multiplicity in the context of quality of life studies. An example of sequential testing is used to illustrate model selection in Chapter 2. The important issues of design and sample size requirements are presented throughout the book.

While not all topics are covered in sufficient depth, the book is remarkable in the breadth of material covered in just 350 pages of text. The authors also provide a very authoritative list of references and regulatory guidances and other documents.

This is a very new and unique book that covers the gamut of statistical issues through all phases of drug development. Shao is a distinguished professor from Wisconsin and Chow teaches at Duke University and formerly at Temple but is known for his long career in the pharmaceutical industry.
The book is good for biostatisticians and regulatory affairs specialists as a reference source. All the key statistical issues are addressed and the reader is given the perspective of the ICH and FDA guidance documents. The underlying statistical methodology that justifies the recommendations in the guidances is presented. This is a state-of-the-art book. Shao and Pigeot produced some of the recent research in individual bioequivalence that established a bootstrap procedure as an appropriate way to construct confidence intervals for the problem. Their method is recommended in an FDA guidance document.

But more than just this one example, all the key issues that have been the subject of FDA workshops over the past several years are addressed in this book. These topics include calibration, assay and assay validation, dissolution testing, stability analysis, shelf life estimation, bioequivalence, randomization and blinding, what constitutes substantive evidence in clinical development, therapeutic equivalence and noninferiority, Bayesian approaches in clinical trials, problems involving missing and incomplete data, longitudinal methods, meta-analysis, quality of life studies and instrument validation, and medical imaging.

Other prevalent issues in clinical trials include group sequential methods, hierarchical Bayesian models and multiple testing. These issues are not covered as much in this text as the others we have mentioned. But there is some discussion of multiplicity in the context of quality of life studies. An example of sequential testing is used to illustrate model selection in Chapter 2. The important issues of design and sample size requirements are presented throughout the book.

While not all topics are covered in sufficient depth, the book is remarkable in the breadth of material covered in just 350 pages of text. The authors also provide a very authoritative list of references and regulatory guidances and other documents.

I received the book the day before I needed it in class the next morning, perfect timing. I am very pleased with my order.
Thank you.

This book came in a very timely matter... even sooner then I was expecting it. The book was in great condition and packaged well so it did not get trashed during the shipping process. Was very happy with this purchase.

this is the most updating book ive ever seen and it is not available in our country that is why i would like to get one as soon as possible to further my studies. please can any boy be of help i can send a person to the u.k to pick ut up thanks tiki.

Basic concepts of tabletting, capsules,other formulation explained in good details. One shop stop for Industry/industrial Pharmacy students.

This book was eye opening to me. Because the author limits his scope to 100 drugs, he was able teach me the philosophy and some history behind the creation of the most useful drugs of today. As an experienced physician, the author is able to insert is own opinions and experiences about his chosen top 100 drugs. This makes this book much more useful to the average person then those other "pill books" which cram thousands of drugs and mind boggling technical info into a single book. If you have found yourself caught up in, and maybe discouraged by, the "natural supplements" craze (like I have), then you may find this book will bring you back into the 20th centry of safe FDA approved drugs.